Terms: = Thyroid cancer AND PTCH1, RP11-435O5_3, Q13635, PTCH, 5727, HPE7, FLJ26746, NBCCS, BCNS, PTC1, ENSG00000185920, FLJ42602 AND Treatment
47 results:
1. Evaluating the Correlation of Hedgehog Pathway with Claudin-1 Expression in Invasive Breast cancer.
Chen D; Cheng X
Cell Mol Biol (Noisy-le-grand); 2023 Feb; 69(2):60-66. PubMed ID: 37224045
[TBL] [Abstract] [Full Text] [Related]
2. Silencing NEAT1 suppresses thyroid carcinoma via miR-126/NEAT1/VEGFA axis.
Zeng W; Lin Y; Lin H; Wu X
Front Biosci (Landmark Ed); 2020 Jan; 25(3):564-576. PubMed ID: 31585904
[TBL] [Abstract] [Full Text] [Related]
3. Impact of ultrasonographic features, cytomorphology and mutational testing on malignant and indeterminate thyroid nodules on diagnostic accuracy of fine needle cytology samples: A prospective analysis of 141 patients.
Fulciniti F; Cipolletta Campanile A; Malzone MG; Chiofalo MG; Capiluongo A; Monaco M; Di Maio N; Sandomenico F; Botti G; Chiappetta G; Vuttariello E; Pezzullo L
Clin Endocrinol (Oxf); 2019 Dec; 91(6):851-859. PubMed ID: 31483883
[TBL] [Abstract] [Full Text] [Related]
4. TSPAN8 promotes cancer cell stemness via activation of sonic Hedgehog signaling.
Zhu R; Gires O; Zhu L; Liu J; Li J; Yang H; Ju G; Huang J; Ge W; Chen Y; Lu Z; Wang H
Nat Commun; 2019 Jun; 10(1):2863. PubMed ID: 31253779
[TBL] [Abstract] [Full Text] [Related]
5. Clinical impact of testing for mutations and microRNAs in thyroid nodules.
Sistrunk JW; Shifrin A; Frager M; Bardales RH; Thomas J; Fishman N; Goldberg P; Guttler R; Grant E
Diagn Cytopathol; 2019 Aug; 47(8):758-764. PubMed ID: 31013001
[TBL] [Abstract] [Full Text] [Related]
6. Relationship between genetic alterations and clinicopathological characteristics of papillary thyroid carcinoma.
Kure S; Wada R; Naito Z
Med Mol Morphol; 2019 Dec; 52(4):181-186. PubMed ID: 30788603
[TBL] [Abstract] [Full Text] [Related]
7. Targetable gene fusions identified in radioactive iodine refractory advanced thyroid carcinoma.
van der Tuin K; Ventayol Garcia M; Corver WE; Khalifa MN; Ruano Neto D; Corssmit EPM; Hes FJ; Links TP; Smit JWA; Plantinga TS; Kapiteijn E; van Wezel T; Morreau H
Eur J Endocrinol; 2019 Apr; 180(4):235-241. PubMed ID: 30668525
[TBL] [Abstract] [Full Text] [Related]
8. FAM129A regulates autophagy in thyroid carcinomas in an oncogene-dependent manner.
Nozima BH; Mendes TB; Pereira GJDS; Araldi RP; Iwamura ESM; Smaili SS; Carvalheira GMG; Cerutti JM
Endocr Relat Cancer; 2019 Jan; 26(1):227-238. PubMed ID: 30400008
[TBL] [Abstract] [Full Text] [Related]
9. Long Non-coding RNA Linc-ROR Is Upregulated in Papillary thyroid Carcinoma.
Zhang R; Hardin H; Huang W; Buehler D; Lloyd RV
Endocr Pathol; 2018 Mar; 29(1):1-8. PubMed ID: 29280051
[TBL] [Abstract] [Full Text] [Related]
10. Upregulation of Tyrosine Kinase FYN in Human thyroid Carcinoma: Role in Modulating Tumor Cell Proliferation, Invasion, and Migration.
Zheng J; Li H; Xu D; Zhu H
Cancer Biother Radiopharm; 2017 Nov; 32(9):320-326. PubMed ID: 29140740
[TBL] [Abstract] [Full Text] [Related]
11. Sunitinib in the treatment of thyroid cancer.
Ferrari SM; Centanni M; Virili C; Miccoli M; Ferrari P; Ruffilli I; Ragusa F; Antonelli A; Fallahi P
Curr Med Chem; 2019; 26(6):963-972. PubMed ID: 28990511
[TBL] [Abstract] [Full Text] [Related]
12. Berberine could inhibit thyroid carcinoma cells by inducing mitochondrial apoptosis, G0/G1 cell cycle arrest and suppressing migration via PI3K-AKT and MAPK signaling pathways.
Li L; Wang X; Sharvan R; Gao J; Qu S
Biomed Pharmacother; 2017 Nov; 95():1225-1231. PubMed ID: 28931215
[TBL] [Abstract] [Full Text] [Related]
13. LncRNA PTCSC3/miR-574-5p Governs Cell Proliferation and Migration of Papillary thyroid Carcinoma via Wnt/β-Catenin Signaling.
Wang X; Lu X; Geng Z; Yang G; Shi Y
J Cell Biochem; 2017 Dec; 118(12):4745-4752. PubMed ID: 28513866
[TBL] [Abstract] [Full Text] [Related]
14. HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.
Cheng L; Jin Y; Liu M; Ruan M; Chen L
Oncotarget; 2017 Mar; 8(12):19843-19854. PubMed ID: 28423638
[TBL] [Abstract] [Full Text] [Related]
15. DNA fragile site breakage as a measure of chemical exposure and predictor of individual susceptibility to form oncogenic rearrangements.
Lehman CE; Dillon LW; Nikiforov YE; Wang YH
Carcinogenesis; 2017 Mar; 38(3):293-301. PubMed ID: 28069693
[TBL] [Abstract] [Full Text] [Related]
16. Hobnail Variant of Papillary thyroid Carcinoma: Clinicopathologic and Molecular Evidence of Progression to Undifferentiated Carcinoma in 2 Cases.
Cameselle-Teijeiro JM; Rodríguez-Pérez I; Celestino R; Eloy C; Piso-Neira M; Abdulkader-Nallib I; Soares P; Sobrinho-Simões M
Am J Surg Pathol; 2017 Jun; 41(6):854-860. PubMed ID: 28009606
[TBL] [Abstract] [Full Text] [Related]
17. Anticancer activity of all-trans retinoic acid-loaded liposomes on human thyroid carcinoma cells.
Cristiano MC; Cosco D; Celia C; Tudose A; Mare R; Paolino D; Fresta M
Colloids Surf B Biointerfaces; 2017 Feb; 150():408-416. PubMed ID: 27829536
[TBL] [Abstract] [Full Text] [Related]
18. Iodine regulates G2/M progression induced by CCL21/CCR7 interaction in primary cultures of papillary thyroid cancer cells with RET/PTC expression.
Zhang YY; Liu ZB; Ye XG; Ren WM
Mol Med Rep; 2016 Oct; 14(4):3941-6. PubMed ID: 27574129
[TBL] [Abstract] [Full Text] [Related]
19. miRNA profiling, detection of BRAF V600E mutation and RET-ptc1 translocation in patients from Novosibirsk oblast (Russia) with different types of thyroid tumors.
Titov SE; Ivanov MK; Karpinskaya EV; Tsivlikova EV; Shevchenko SP; Veryaskina YA; Akhmerova LG; Poloz TL; Klimova OA; Gulyaeva LF; Zhimulev IF; Kolesnikov NN
BMC Cancer; 2016 Mar; 16():201. PubMed ID: 26960768
[TBL] [Abstract] [Full Text] [Related]
20. Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on thyroid cancer.
Ferrari SM; La Motta C; Sartini S; Baldini E; Materazzi G; Politti U; Ruffilli I; Ulisse S; Miccoli P; Antonelli A; Fallahi P
Mini Rev Med Chem; 2016; 16(2):86-93. PubMed ID: 26471970
[TBL] [Abstract] [Full Text] [Related]
[Next]
